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Future Directions in EpidemiologicStudies
of 1,3-Butadiene-Exposed Workers
by John F. Acquavella*
To date, epidemiologic research on 1,3-butadiene has consisted ofcohort mortality studies ofworkers in
the styrene-butadiene rubber(SBR) and butadiene monomer industries. These studies have been extremely
useful both in defining the focus on human health effects to the lymphopoietic cancers and in providing a
perspective on which to evaluate the available animal models for human risk assessment. The next step for
epidemiologic research will involve alymphopoietic cancer case control approach to enable a more precise
assessment ofwhetherthere is arelationshipbetween 1,3-butadiene exposure andlymphopoietic cancer. In
addition, periodic mortality updates of the 1,3-butadiene-exposed worker cohorts will be important to
monitortrends inlymphopoietic cancerratesandtoensurethatothercancerswithlonglatencydonotbegin
to show elevated rates. This paper describes an industry-sponsored program of case-control and cohort
mortality update studies along with the critical elements in research design and analysis for each study.
Epidemiological studies will play an important role in testing hypotheses developed from toxicological
studies about potential biological mechanisms of 1,3-butadiene carcinogenesis in humans.
Introduction
In our attempt to understand the potential human
health risks of exposure to 1,3-butadiene, we are quite
fortunate to have available a considerable amount of
toxicological and epidemiological data. In this latter
regard, theupdate ofthethreeavailableepidemiological
studies (1-3) provides additional information on the
mortality experience of workers with occupational 1,3-
butadiene exposure. The purpose of this paper is to
discuss future areas for epidemiological research. Some
ofthe study areas have already been incorporated into
the International Institute of Synthetic Rubber Pro-
ducer's (IISRP) epidemiology program, funded jointly
by the IISRP and the butadiene monomer producers.
Other study areas are longer term and await develop-
ments in related scientific fields.
Perhaps the best way to set the stage for discussing
future epidemiologicresearchrelated to1,3-butadiene is
to considerthepresent statusofepidemiologic research,
identify existing data gaps and important methodologic
issues that need to be resolved, and plan studies to
address these issues. In addition, this paper discusses
anticipated related toxicological developments and
points outwhere epidemiologic studies cancontribute to
refining or testing specific hypotheses.
Cohort Studies of Worker Mortality
The previous three papers are examples ofhistorical
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prospective cohort (or follow-up) mortality studies
(1-3). Cohort mortality studies begin by defining a
worker population (the cohort) at a point in time (1943
forthesestudies)andfollowingworkersprospectivelyto
assess each individual's vital status at the end of the
study period. Death rates for workers are then com-
pared with general population rates. Additionally, for
large cohorts, there may be comparisons of rates be-
tween exposed andunexposed workers. Since acause of
death is determined for almost all decedents in the
cohort, these studies allow an evaluation ofdeath rates
for workers for many causes of death. However, since
cohort studies typically involve thousands of workers,
assembling detailed exposure data or making exposure
estimates for each worker is often impractical, limiting
the potential to study exposure-disease relationships.
Accordingly, thesecohortstudiesareparticularlyuseful
to assess whether rates for many causes of death are
elevated among worker populations and to generate
hypothesesforfurther, moredetailed, studiesofspecific
occupational subgroups.
Summary ofFindings
A comprehensive review of 1,3-butadiene epidemi-
ologyisbeyondthe scopeofthispaperandisthetopic of
the succeeding two papers (4,5). However, abriefsum-
maryoftheavailableepidemiologicfindingsisprovided,
since future trends in epidemiologic research evolve
from the context of our current state of scientific
knowledge.J. F. ACQUAVELLA
Studies of styrene-butadiene rubber (SBR) workers
and butadiene monomer employees show a generally
favorablemortalityprofileofloweroverallmortalityand
total cancer mortality compared to general population
rates (1-3,6-8). Further, mortalityfrommostcancersis
less frequent than expected. However, mortality from
lymphopoietic cancer [International Classification of
Diseases (ICD), 8th revision, 200-209] emerges as a
potential cause for concern, since each study has a sub-
group of workers with an elevated mortality rate for a
type oflymphopoietic cancer. These excesses generally
involve shorter term workers, and there is no consis-
tencyinthelymphopoietic cancercelltypes across stud-
ies. In addition, analyses of the lymphopoietic cancer
deaths do not indicate elevated mortality rates among
workers with longest duration of employment and/or
long latency, which would be typical for an exposure-
related excess. Nevertheless, these lymphopoietic can-
cer findings deserve further follow-up and, therefore,
are the focus ofthe current IISRP-sponsored epidemi-
ologic research program. Thus, for now, these cohort
mortality studies have narrowed the scope of 1,3-
butadiene-related human health research to lymphopoi-
eticcancers. Thisisimportantinlightoftheresultsfrom
the B6C3F1 mouse studies that show a striking 1,3-
butadiene-related excess for thymic lymphomas, but
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also show tumor excesses for several other organ sys-
tems (9).
Impact on Risk Assessment
While the cohort studies of 1,3-butadiene-exposed
workers have provided an important perspective on
worker mortality rates, these studies are often not use-
ful forrisk assessment modeling because exposure esti-
mates are not available for individual workers. How-
ever, despitethislimitation, thehumandatacanbeused
to evaluate projected worker mortality based on risk
estimates (unit risks) derived from the chronic rat (10)
and mouse (11) bioassays. This analysis requires two
simplifyingassumptions: a)thatworkersonthe average
were exposed to a specific exposure level (in this exam-
ple, 1, 5, and 10 ppm were used since these levels are
consistent with the available monitoring data as shown
inFig. 1);and b)thatanyexcessmortalitywouldbefrom
lymphopoietic cancer (following directly from the pre-
vious summary of findings).
For example, based on the largest published SBR
workers study (8) to date, Figure 2 compares the ob-
servedhumanlymphopoieticcancermortality(thewhite
bar) and the mortality predicted based on the unit risk
estimates from the rat (10) (grey bar) and mouse (11)
18% -
16% -
14% -
12% -
10% -
8% -
6%
4%
2%
0%
4 0.8 PPM 0.5-1 PPM 1-2 PPM 2-3 PPM 3-4 PPM 4-5 PPM 5-10 PPM 10-28 PPM 25 PPM
EXPOSURE IN PARTS PER MILLION
FIGURE 1. 1,3-butadiene job exposure data from all monitored jobs, 1981 to 1987.
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FIGURE 2. Lymphopoietic cancer among SBR workers: comparison with rodent model predictions.
(black bar) models, assuming that the average worker-
exposure levels were 1, 5, and 10 ppm. The horizontal
line on the graph is the level where the animal models
significantlyoverpredictthe observed humanmortality.
The numbers in parentheses on top ofthe bars are the
probabilities of seeing as few or fewer deaths among
SBR workers if the excess cancer risk was as great as
thatpredictedbythe animalmodels. Fromthisfigure, it
is clear that the mouse model significantly overpredicts
human mortality at average exposure levels of 1 ppm
andgreaterlevels, which currentmonitoringdatatell us
still exist in SBR facilities (12). Projections based onthe
rat model are less severe, but they still seem to over-
predict human mortality at levels of 5 ppm or greater.
Clearly then, to the extent that the two assumptions
above are reasonable, the human data offer a perspec-
tive on the worker mortality projections, based on the
existing animal models for 1,3-butadiene. In the same
way, future developments from toxicological studies
should be evaluated, where possible, against the avail-
able epidemiological data.
Importance of Continued Follow-up
In light of the approximate 40-year study period for
each ofthese cohorts, the question arises: Is there any-
thingtobegainedbycontinuingthefollow-upperiodfor
these workers? Clearly, the answer to this question is
that much remains to be learned from cohort mortality
studies of 1,3-butadiene-exposed workers. Specifically,
until more is known aboutthe applicability ofthe animal
models, the continued monitoring ofthe workers' mor-
tality experience will be a critical component of any
future research program. In this regard, maintaining a
current data base ofhuman mortality will be important
to assesstemporaltrendsin cancermortality, especially
for cancers that may occurwith longlatent periods, and
to aid inevaluating newleads fromcontinuedtoxicologi-
cal research. Accordingly, future research priorities
within the IISRP include a continuation of the SBR
workers mortality study soon after completing detailed
studies of the relationship between lymphopoietic can-
cer and 1,3-butadiene exposure. Obviously, continued
follow-up of the National Institute for Occupational
Safety and Health (NIOSH) (1) and Texaco (3) cohorts
would provide useful parallel efforts.
Four modifications should be considered to improve
the datafromfuture cohortmortality studies. First, the
usefulness ofthe humanmortalitydatawouldbegreatly
improved by a realignment ofthe lymphopoietic cancer
categories used in the mortality analyses. This realign-
ment should reflect the current thinking on the charac-
teristics of the individual lymphopoietic cancer cell
types. The three studies reported today have employed
lymphopoietic cancer groups that mix potentially re-
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Table 1. Lymphopoietic cancer groupings used in the
existing 1,3-butadiene epidemiology studies.
Category Includes (ICD 8a)
Lympho/reticulo sarcoma Lymphosarcoma (200)
Reticulum cell sarcoma (200)
Hodgkin's disease Hodgkin's lymphoma (201)
Other lymphopoietic tissue Giant follicular and other lymphoma
(202)
Multiple myeloma (203)
Polycythemia vera (208)
Leukemia and aleukemia Lymphatic leukemia (204)
Myeloid leukemia (205)
Monocytic leukemia (206)
Leukemia not otherwise specified
(207)
aIntemational Classification of Diseases, 8th revision.
lated and unrelated cell types (Table 1). For example,
the category entitled "cancer ofother lymphatic tissue"
mixes giant follicular and other lymphomas, multiple
myeloma, and polycythemia vera. Similarly, the leu-
kemia category combines lymphoid, myeloid, mono-
cytic, and leukemia not otherwise specified. A better
grouping would have separate categories for the non-
Hodgkin's lymphomas (lymphosarcoma, reticulum cell
sarcoma, and giant follicularlymphoma), Hodgkin's dis-
ease, multiple myeloma, and each leukemia cell type.
Mortality analyses presented in this way would then
allow an evaluation ofresults within and across studies
for consistency and for compatibility with advancing
knowledge of biological mechanisms.
A second suggestion would be to use local mortality
rates for comparisons ofworker mortality. At present,
interpretationofSMRsfor1,3-butadiene-exposed work-
ers is clouded by variability that is introduced by using
U.S. mortality rates as a basis for evaluating worker
mortality at plants scattered throughout the U.S. and
Canada. MortalityratesforU.S. statesandcountiesand
for Canadian provinces are available from several
sources and should be incorporated in future mortality
studies. To date, only the previously published Texaco
study used local rates for their mortality analysis (7).
The importance of using local rates was vividly illus-
trated in that study, as comparisons based onboth U.S.
and local rates showed that local general population
lymphosarcoma rates were 30% higher than U.S. rates.
Athird suggestion would be to presentlymphopoietic
cancer SMRs for various latency/duration of employ-
ment subgroups. The purpose of this suggestion is to
have the authors specify which, if any, subgroups are
showing elevated lymphopoietic cancer rates. At that
point, data across studies could be evaluated as sug-
gested by Doll (13) to see ifincreased risk varies appro-
priately with intensity and duration of exposure and
time after exposure begins and ends; and is observed
repeatedly in different circumstances. At present, it is
impossible to apply these criteria to the 1,3-butadiene
literature.
A final methodologic suggestion would be to evaluate
lifetime work histories for a sample of short-term em-
ployees in each ofthese cohort studies. This evaluation
would reviewworkexperience before and afteremploy-
ment in 1,3-butadiene-related occupations. Clearly, the
findings oflymphopoietic cancer excesses among short-
termworkerssuggeststhatpossiblelongeremployment
in other industries must be considered in interpreting
the results in 1,3-butadiene-related industries.
Lymphopoietic Cancer Case Control
Studies
Prior to initiating another mortality update of the
IISRP SBR workers cohort study (8), the IISRP re-
search program is focusing on detailed studies of a po-
tentialrelationshipbetween 1,3-butadieneexposureand
lymphopoietic cancer(s). The most common research
design forthis purpose is the nested case-control study.
The term "nested" refers to the fact that cases and
controls are selected from within the cohort for which
mortality data are available. In contrast to cohort stud-
ies, case-control studies usually concentrate on one dis-
ease orarelated groupofdiseasesand comparethe odds
of previous exposure for those with the disease (the
cases) versus those without the disease (the controls).
Since nested case-control studies focus on a small sub-
group of an occupational cohort (namely those with a
specific disease and a sample ofnondiseased workers),
considerably more attention can be given to the data
available for each study subject. This allows detailed
evaluation in two critical areas: validation of lympho-
poietic cancer diagnoses and estimation of historical
1,3-butadiene exposures.
Validation of lymphopoietic cancer diagnoses is ex-
tremelyimportantforcase-control studiesinlightofthe
unreliability oflymphopoietic cancerdiagnoses on death
certificates. Perhaps thebeststudy onthisissue todate
wasconductedbythe NationalCenterforHealthStatis-
tics. In this study, Percy et al. (14) looked at the death
certificate diagnosis for more than 48,000 cancer deaths
from the Third National Cancer Survey and compared
this information to the primary cancer site reported on
the hospital diagnosis. This analysis showed consider-
able underdiagnosis and misclassification of the indi-
viduallymphopoieticcancertypes. Forexample, Table2
shows that only 79.9% oflymphocytic leukemia deaths
would have been detected from death certificate diag-
noses. Further, of those specified as lymphocytic leu-
kemias on death certificates, only 86.3% could be con-
firmed from hospital records. A more recent study by
Gittlesohn, for the period 1968 to 1978, showed a one-
third decline in lymphosarcoma and reticulum cell sar-
comaas death certificate diagnoses and acorresponding
doubling of the number of deaths attributed to un-
specified malignancy of lymphoid tissue (15). Clearly
then, case-controlresearchshouldincorporateconfirma-
tion of the diagnoses and cell type, when possible, for
eachlymphopoietic cancer. Otherwise, the valid assess-
ment ofthe relationship between 1,3-butadiene and the
individual lymphopoietic cancer cell types will be ob-
scured by the mixing of unrelated lymphopoietic and
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Table 2. Detection and confirmation rates for lymphopoietic
cancers from the Third National Cancer Survey.a
Percent Percent
ICD 8b Primary site Number detected confirmed
200,202 Non-Hodgkin's lymphoma 1562 83.2 88.4
201 Hodgkin's disease 572 86.7 92.5
203 Multiple myeloma 699 96.6 98.1
204 Lymphocytic leukemia 743 79.9 86.3
205 Myeloid leukemia 1107 76.2 92.2
206 Monocytic leukemia 98 57.1 53.8
207 Otherand unspecified leukemia 204 73.0 34.3
aFrom Percy et al. (12).
bIntemational Classification of Diseases, 8th revision.
other cancers in the case group.
Equally important for case-control studies is the
proper estimation ofhistorical 1,3-butadiene exposures
for cases and controls. Many ofthe large petrochemical
companies have had collaborative epidemiology and in-
dustrialhygieneprograms to assessstrategiesforretro-
spective exposure assessment. From these efforts, it
hasbeen shown that exposure estimatingschemes must
consideravailableplantmonitoringdataaswellasplant-
specific changes in engineering controls and work prac-
tices (especially use of personal protective equipment)
thatcould have affected workplace exposures. Jobtitles
canoftenbemisleading, especiallyininterindustrystud-
ies, and should be used with caution as an indicator of
workerexposure. Abetterapproachwould betousejob
titles in conjunction with a detailed analysis of plant-
specific monitoring data, engineering controls for spe-
cific time periods, and work practices. Once this back-
ground work is done, exposures can be estimated for
eachjob title and cumulative exposure scorescalculated
for each case and control based on their work history.
Wheneverpossible, exposure estimates shouldbe align-
ed with exposure values as a guide to the scaling of
exposure scores in subsequent dose-response analyses.
A lymphopoietic cancer case-control study is currently
underwayusingcasesandcontrolsselectedfromtheIISRP
SBR workers' cohort. This studyisbeingconducted intwo
phases, with phase I expected to be completed by the
summer of 1988 (Mantanoski et al., unpublished report).
The respective components ofphase I and II case control
studies are detailed in Table 3.
Phase I is usingdiagnosticinformation from workers'
death certificates toselect casesoflymphopoietic cancer
based oneithertheunderlyingoracontributing cause of
death. Exposure to 1,3-butadiene and styrene was esti-
mated for both cases and controls in two steps. First, a
dictionary ofjob titles was developed across all eight
plants included in the cohort study. Then an industry
workgroup rated the exposure potential ofeachjobtitle
onhigh/medium/low/no and 0 to 10 scales. These ratings
reflectedtheopinions oftheindustryworkgroup anddid
not employ available monitoring data. From these ex-
posure estimates, acumulative exposurepotential score
was developed for each worker as the sum of the ex-
posure score times the time spent in each job. The
analysis is currently ongoing to determine whether
Components
Case
ascertainment
Case validation
Exposure
assessment
Data analysis
Time frame
Phase I
Death certificates
No
Judgments across
eight plants; no
use of moni-
toring data,
process changes,
or work
practices
Tests for
association and
dose response
September 1986-
June 1988
Phase II
May add cases
from medical
record review
Yes
Local personnel
make estimates
based on moni-
toring data,
process changes,
and work
practices
Tests for
association and
dose response
January 1989-
December 1991
cases tended to spend more time injobsjudged to have
higher exposure potential than did the controls.
The phase II lymphopoietic cancer case control study
will require roughly 18 to 24 months for completion. In
this study, medical records will be reviewed to verify
diagnoses and specify cell types for all cases. This will
allowevaluationofriskforspecific lymphopoietic cancer
cell types. In conjunction with medical record review,
exposure assessment will be improved by employing all
available monitoring data and the knowledge of local
plantindustrialhygieneand technicalpersonneltodocu-
ment changes in equipment and work practices that
might have affected worker exposures.
Epidemiology Studies Suggested by
Toxicological Research
The next stage of future epidemiological studies de-
pends on advances from toxicological studies into mech-
anisms of 1,3-butadiene activity in animal and in vitro
systems and on the applicability ofthis research to our
understandingofhuman cancerrisk. Manyofthefollow-
ing comments will apply as much to 1,3-butadiene as
they do to a number of other chemicals that are the
subject of ongoing toxicological research. Such studies
will ultimately arise in two areas: a) studies of cancer
risk in populations with potentially increased suscepti-
bility to effects of 1,3-butadiene; and b) correlations of
biological markers of intermediate disease stages with
1,3-butadiene exposure. Ofthese, studies ofpotentially
susceptible subpopulations seem most likely to occur
within the nextdecade, sothe ensuingdiscussion willbe
confined to some preliminary thoughts in this area.
By definition, a susceptible subpopulation is one that
has ahigh prevalence of atrait resultingin an increased
cancer risk. Forexample, anumber ofyears ago Keller-
man et al. (16) suggested that individuals with higher
levels ofaryl hydrocarbon hydroxylase (AHH) were at
increased risk for lung cancer. Soon thereafter, Paigen
et al. (17) presented data to suggest that Kellerman's
Table 3. Lymphopoietic cancer case-control study.
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findings were a consequence oflung cancer, rather than
a risk factor. However, had AHH proven to be an
indicator of increased lung cancer risk, it would have
proved useful foridentifying susceptible individuals and
would have shown obvious implications forresearch and
cancer prevention.
As research into the mechanisms ofchemical carcino-
genesis develops, traits that modify cancer incidence in
experimental animals will need to be evaluated fortheir
applicability forhuman cancerriskassessment. Ifanalo-
gous mechanisms are thought to operate for humans,
any worker population with a high prevalence of that
trait would be a potentially susceptible subpopulation.
Epidemiological studies of these populations would be
useful as the ultimate test ofthesehypothesis, by allow-
ing a comparison of the observed disease occurrence
versus that predicted based on the experimental data.
Clearly, there will be several intermediate steps that
remain to be done to assess whether potential mech-
anisms from experimental studies have any relevance
for human populations. Provided these intermediate
steps can be done, the existence ofa potential biological
mechanism can be incorporated directly into the plan-
ning of an appropriate epidemiologic study. For exam-
ple, it seems likely that a biological mechanism sugges-
tive of increased susceptibility among worker popula-
tionswouldhave amultiplicative effectonhuman cancer
incidence. Accordingly, the expectation of a multi-
plicative model can be incorporated into sample size
calculations, in proportion to the prevalence ofthe trait
among specific populations, to assess the number of
workers necessary to address this hypothesis. Most
often, thiswillrequire asmallerstudypopulation thanis
traditionally thought necessary for an occupational epi-
demiologic study.
Conclusion
In conclusion, the available butadiene monomer and
SBR worker-cohort studies have beenextremely useful
in documenting the generally favorable mortality pat-
terns among 1,3-butadiene-exposed workers and in
pointing outthe need forfurther, moredetailed, studies
focusing onlymphopoietic cancers. Thesecohort studies
have also provided a basis for evaluating projections of
worker mortality based on the available animal models.
The next step for epidemiologic research will employ
nested case-control studies for a more precise assess-
ment ofwhether there is arelationship between 1,3-bu-
tadiene exposure and lymphopoietic cancer. Periodic
mortality updates of 1,3-butadiene-exposed worker co-
horts will be important to monitor trends in lympho-
poietic cancer rates and to ensure that long latency
cancers do not begin to show elevated rates. Finally,
epidemiological studies developed from toxicological
studies willplay animportantrole intestinghypotheses
about biological mechanisms of human carcinogenesis.
These studies will require close collaboration between
toxicologists, industrial hygienists, technical plant per-
sonnel, andepidemiologists inplanning, conducting, and
analyzing these studies.
I would like to acknowledge the useful discussions and input from
S. Cowles, B. Divine, M. Bird, R. Hinderer, F. Thomas, andW. Davis
during the preparation ofthis manuscript.
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